Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ: IRON )

33.75 +0.40 (+1.20%)
Streaming Delayed Price Updated: 2:12 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,273
Open 33.20
Bid (Size) 33.62 (4)
Ask (Size) 33.74 (1)
Prev. Close 33.35
Today's Range 31.60 - 34.40
52wk Range 25.60 - 77.60
Shares Outstanding 5,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire

Performance

YTD
-43.50%
-43.50%
1 Month
+25.00%
+25.00%
3 Month
-48.06%
-48.06%
6 Month
-37.24%
-37.24%
1 Year
+4.17%
+4.17%

More News

Read More
IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024
Via InvestorPlace
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
NASDAQ:IRON Shareholder Notice: Investigation over Potential Wrongdoing at Disc Medicine Opco Inc
Via SBWire
Top 3 Health Care Stocks You'll Regret Missing This Month
Via Benzinga
Gold Gains 1%; CXApp Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response
Via Benzinga
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study
Via Investor's Business Daily
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
From Disc Medicine Inc
Via GlobeNewswire
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
Via Talk Markets
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
From Disc Medicine Inc
Via GlobeNewswire
Blue Bird Posts Upbeat Results, Joins Oil-Dri Corporation of America, Eagle Bulk Shipping And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting
From Disc Medicine Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.